Relevant Outcome Measures for Creatine Transporter Deficiency Patient
NCT ID: NCT06018519
Last Updated: 2025-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
197 participants
INTERVENTIONAL
2023-03-13
2026-12-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A retrospective study with questionnaires identified that most CTD patients had moderate to severe intellectual disability. Less than one third of patients were able to speak in sentences. Seizures were present in 59% of the patients. 41% had autistic features. Motor dysfunction was mentioned in 58%, and gastrointestinal symptoms were reported in 35% of the patients.
Several new therapeutic avenues are currently emerging in this disease for which no treatment has been available until now : cyclocreatine (interesting but unfortunately with very little clinical applicability due to its toxicity; dodecyl creatine ester incorporated into lipid nanocapsules with intranasal administration; pharmaco-chaperoning (for the folding-deficient creatine transporter variants, Ultragenyx pharmaceuticals new prodrug designed to deliver creatine to the brain (UX068). These new pharmacological treatment options may offer future opportunities to improve cognition in CTD patients.
A key issue is to determine outcome measures that are accessible to these patients, despite the importance of their cognitive deficit. In a preliminary study (on 31 CTD patients), investigators showed for example, that 75% of patients were unable to perform a Wechsler scale, which is one of the most used neuropsychological test to determine patient IQ (intelligence quotient). Most of the existing cognitive tests were developed to distinguish typically developing persons and ID (intellectual disability) patients, leading to a floor effect in the latter who systematically fail these tests. Therefore, these tests are not adapted to capture the potential effect of a drug in ID patient group. The identification of reliable and sensitive outcome measures for use in clinical trials in ID patients was recognized as a priority in a meeting convened by the NIH. N-of-1 trials (also called Single-Case Experimental Designs or SCEDs) appear of great interest for rare diseases, statistical power coming from the number of repeated measures, which leads to choose outcome measures that can be repeated multiple times.
This innovative study will allow to efficiently preparing future therapeutic trials, by specifying the phenotype of the patients, and by determining the most adapted outcome measures taking into account their cognitive deficiency and the type of experimental design to be used in the context of rare diseases.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Males With Creatine Transporter Deficiency
NCT02931682
Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients
NCT01023451
Genetics of Congenital Heart Disease
NCT01192048
Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study
NCT06792448
Cardiac Outcome Measures in Children With Muscular Dystrophy
NCT01066455
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CTD male patients
Case group 24 male CTD patients having a confirmed mutation in the SLC6A8 gene, aged \> 5 to \< 35 years.
Clinical endpoints
1. Number of epileptic seizures
2. Change in antiepileptic treatment (increase or decrease)
3. Visual analogical scale on a target symptom defined with the parents,
4. CGI,
5. Actimetry data over 24 hours,
6. Podometry data over 24 hours,
7. 6 minutes' walk test,
8. Clinical examination
9. Feasibility of performing an MRI without any anesthesia on a mock scanner
Parental questionnaires
10- Adaptive assessment with Vineland Adaptive Behavior scale II,
11- Mac Arthur questionnaire regarding language,
12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),
13- Dunn sensory profile,
14- Aberrant Behavior Checklist,
15- Nisonger Child Behavior Rating form,
16- Social Responsiveness Scale 2,
17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)
Quality of life scale
18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
Cognitive assessments
19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible
20- CPM-BF
21- Simple reasoning task on tablet (match-to-sample task)
22- Implicit rules learning (modified Brixton),
23- 4 sub-tests from the WPPSI-IV ("zoo location" to assess spatial memory, "block design" to assess visuo-constructive abilities, "bug search" , "cancellation"),
24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),
25- Elementary visuo-spatial perception (on tablets)
Language assessments
26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),
27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),
28- Automatic language analysis (during a 10 minutes interaction, play).
Motor assessments
29- Kinematic task (specifically designed),
30- Purdue-Pegboard test,
31- Renzi test
Social assessments
32- Eye-tracking analysis of social visual scenes and social preference index (movies),
33- theory of mind assessment,
34- ADOS scale (Autism Spectrum Disorder),
35- sensitivity to inequality,
36- pro-social behaviors (help of the psychologist)
3T MRI
37- Structural, metabolic and functional data
Cardiac assessments
38- ECG
39- Ultrasound
Biological collection
40- Blood sample
41- Urinary sample
42- Superficial skin biopsy
Sex and chronological age matched male controls
Control group 24 male, sex and chronological age matched controls, aged \> 5 to \< 35 years
Clinical endpoints
1. Number of epileptic seizures
2. Change in antiepileptic treatment (increase or decrease)
3. Visual analogical scale on a target symptom defined with the parents,
4. CGI,
5. Actimetry data over 24 hours,
6. Podometry data over 24 hours,
7. 6 minutes' walk test,
8. Clinical examination
9. Feasibility of performing an MRI without any anesthesia on a mock scanner
Cognitive assessments
19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible
20- CPM-BF
21- Simple reasoning task on tablet (match-to-sample task)
22- Implicit rules learning (modified Brixton),
23- 4 sub-tests from the WPPSI-IV ("zoo location" to assess spatial memory, "block design" to assess visuo-constructive abilities, "bug search" , "cancellation"),
24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),
25- Elementary visuo-spatial perception (on tablets)
Language assessments
26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),
27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),
28- Automatic language analysis (during a 10 minutes interaction, play).
Motor assessments
29- Kinematic task (specifically designed),
30- Purdue-Pegboard test,
31- Renzi test
Social assessments
32- Eye-tracking analysis of social visual scenes and social preference index (movies),
33- theory of mind assessment,
34- ADOS scale (Autism Spectrum Disorder),
35- sensitivity to inequality,
36- pro-social behaviors (help of the psychologist)
3T MRI
37- Structural, metabolic and functional data
Biological collection
40- Blood sample
41- Urinary sample
42- Superficial skin biopsy
Sex and mental age matched male controls
Control group 24 male, sex and mental age matched controls, aged \> 2 to \< 8 years
Clinical endpoints
1. Number of epileptic seizures
2. Change in antiepileptic treatment (increase or decrease)
3. Visual analogical scale on a target symptom defined with the parents,
4. CGI,
5. Actimetry data over 24 hours,
6. Podometry data over 24 hours,
7. 6 minutes' walk test,
8. Clinical examination
9. Feasibility of performing an MRI without any anesthesia on a mock scanner
Cognitive assessments
19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible
20- CPM-BF
21- Simple reasoning task on tablet (match-to-sample task)
22- Implicit rules learning (modified Brixton),
23- 4 sub-tests from the WPPSI-IV ("zoo location" to assess spatial memory, "block design" to assess visuo-constructive abilities, "bug search" , "cancellation"),
24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),
25- Elementary visuo-spatial perception (on tablets)
Language assessments
26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),
27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),
28- Automatic language analysis (during a 10 minutes interaction, play).
Motor assessments
29- Kinematic task (specifically designed),
30- Purdue-Pegboard test,
31- Renzi test
Social assessments
32- Eye-tracking analysis of social visual scenes and social preference index (movies),
33- theory of mind assessment,
34- ADOS scale (Autism Spectrum Disorder),
35- sensitivity to inequality,
36- pro-social behaviors (help of the psychologist)
Typically developed children
Control group 80 typically developed children aged \> 2 to \< 8 years, which corresponds to the mental age of CTD patients.
40 children aged \> 2 to \< 5 years, and 40 children aged \> 6 to \< 8 years will perform the newly developed outcome measures.
Cognitive assessments
19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible
20- CPM-BF
21- Simple reasoning task on tablet (match-to-sample task)
22- Implicit rules learning (modified Brixton),
23- 4 sub-tests from the WPPSI-IV ("zoo location" to assess spatial memory, "block design" to assess visuo-constructive abilities, "bug search" , "cancellation"),
24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),
25- Elementary visuo-spatial perception (on tablets)
Language assessments
26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),
27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),
28- Automatic language analysis (during a 10 minutes interaction, play).
Motor assessments
29- Kinematic task (specifically designed),
30- Purdue-Pegboard test,
31- Renzi test
Social assessments
32- Eye-tracking analysis of social visual scenes and social preference index (movies),
33- theory of mind assessment,
34- ADOS scale (Autism Spectrum Disorder),
35- sensitivity to inequality,
36- pro-social behaviors (help of the psychologist)
CTD female patients
15 female CTD patients having a confirmed mutation in the SLC6A8 gene, aged \>5 to \< 60 years
Clinical endpoints
1. Number of epileptic seizures
2. Change in antiepileptic treatment (increase or decrease)
3. Visual analogical scale on a target symptom defined with the parents,
4. CGI,
5. Actimetry data over 24 hours,
6. Podometry data over 24 hours,
7. 6 minutes' walk test,
8. Clinical examination
9. Feasibility of performing an MRI without any anesthesia on a mock scanner
Parental questionnaires
10- Adaptive assessment with Vineland Adaptive Behavior scale II,
11- Mac Arthur questionnaire regarding language,
12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),
13- Dunn sensory profile,
14- Aberrant Behavior Checklist,
15- Nisonger Child Behavior Rating form,
16- Social Responsiveness Scale 2,
17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)
Quality of life scale
18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
Cognitive assessments
19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible
20- CPM-BF
21- Simple reasoning task on tablet (match-to-sample task)
22- Implicit rules learning (modified Brixton),
23- 4 sub-tests from the WPPSI-IV ("zoo location" to assess spatial memory, "block design" to assess visuo-constructive abilities, "bug search" , "cancellation"),
24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),
25- Elementary visuo-spatial perception (on tablets)
Language assessments
26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),
27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),
28- Automatic language analysis (during a 10 minutes interaction, play).
Motor assessments
29- Kinematic task (specifically designed),
30- Purdue-Pegboard test,
31- Renzi test
Social assessments
32- Eye-tracking analysis of social visual scenes and social preference index (movies),
33- theory of mind assessment,
34- ADOS scale (Autism Spectrum Disorder),
35- sensitivity to inequality,
36- pro-social behaviors (help of the psychologist)
3T MRI
37- Structural, metabolic and functional data
Cardiac assessments
38- ECG
39- Ultrasound
Biological collection
40- Blood sample
41- Urinary sample
42- Superficial skin biopsy
Sex and mental age matched female controls
Control group 15 female, sex and mental age matched controls, aged \> 2 to \< 8 years
Clinical endpoints
1. Number of epileptic seizures
2. Change in antiepileptic treatment (increase or decrease)
3. Visual analogical scale on a target symptom defined with the parents,
4. CGI,
5. Actimetry data over 24 hours,
6. Podometry data over 24 hours,
7. 6 minutes' walk test,
8. Clinical examination
9. Feasibility of performing an MRI without any anesthesia on a mock scanner
Cognitive assessments
19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible
20- CPM-BF
21- Simple reasoning task on tablet (match-to-sample task)
22- Implicit rules learning (modified Brixton),
23- 4 sub-tests from the WPPSI-IV ("zoo location" to assess spatial memory, "block design" to assess visuo-constructive abilities, "bug search" , "cancellation"),
24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),
25- Elementary visuo-spatial perception (on tablets)
Language assessments
26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),
27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),
28- Automatic language analysis (during a 10 minutes interaction, play).
Motor assessments
29- Kinematic task (specifically designed),
30- Purdue-Pegboard test,
31- Renzi test
Social assessments
32- Eye-tracking analysis of social visual scenes and social preference index (movies),
33- theory of mind assessment,
34- ADOS scale (Autism Spectrum Disorder),
35- sensitivity to inequality,
36- pro-social behaviors (help of the psychologist)
Sex and chronological age matched female controls
Control group 15 female, sex and chronological age matched controls, aged \> 5 to \< 60 years
Clinical endpoints
1. Number of epileptic seizures
2. Change in antiepileptic treatment (increase or decrease)
3. Visual analogical scale on a target symptom defined with the parents,
4. CGI,
5. Actimetry data over 24 hours,
6. Podometry data over 24 hours,
7. 6 minutes' walk test,
8. Clinical examination
9. Feasibility of performing an MRI without any anesthesia on a mock scanner
Cognitive assessments
19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible
20- CPM-BF
21- Simple reasoning task on tablet (match-to-sample task)
22- Implicit rules learning (modified Brixton),
23- 4 sub-tests from the WPPSI-IV ("zoo location" to assess spatial memory, "block design" to assess visuo-constructive abilities, "bug search" , "cancellation"),
24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),
25- Elementary visuo-spatial perception (on tablets)
Language assessments
26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),
27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),
28- Automatic language analysis (during a 10 minutes interaction, play).
Motor assessments
29- Kinematic task (specifically designed),
30- Purdue-Pegboard test,
31- Renzi test
Social assessments
32- Eye-tracking analysis of social visual scenes and social preference index (movies),
33- theory of mind assessment,
34- ADOS scale (Autism Spectrum Disorder),
35- sensitivity to inequality,
36- pro-social behaviors (help of the psychologist)
3T MRI
37- Structural, metabolic and functional data
Biological collection
40- Blood sample
41- Urinary sample
42- Superficial skin biopsy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical endpoints
1. Number of epileptic seizures
2. Change in antiepileptic treatment (increase or decrease)
3. Visual analogical scale on a target symptom defined with the parents,
4. CGI,
5. Actimetry data over 24 hours,
6. Podometry data over 24 hours,
7. 6 minutes' walk test,
8. Clinical examination
9. Feasibility of performing an MRI without any anesthesia on a mock scanner
Parental questionnaires
10- Adaptive assessment with Vineland Adaptive Behavior scale II,
11- Mac Arthur questionnaire regarding language,
12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),
13- Dunn sensory profile,
14- Aberrant Behavior Checklist,
15- Nisonger Child Behavior Rating form,
16- Social Responsiveness Scale 2,
17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)
Quality of life scale
18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
Cognitive assessments
19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible
20- CPM-BF
21- Simple reasoning task on tablet (match-to-sample task)
22- Implicit rules learning (modified Brixton),
23- 4 sub-tests from the WPPSI-IV ("zoo location" to assess spatial memory, "block design" to assess visuo-constructive abilities, "bug search" , "cancellation"),
24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),
25- Elementary visuo-spatial perception (on tablets)
Language assessments
26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),
27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),
28- Automatic language analysis (during a 10 minutes interaction, play).
Motor assessments
29- Kinematic task (specifically designed),
30- Purdue-Pegboard test,
31- Renzi test
Social assessments
32- Eye-tracking analysis of social visual scenes and social preference index (movies),
33- theory of mind assessment,
34- ADOS scale (Autism Spectrum Disorder),
35- sensitivity to inequality,
36- pro-social behaviors (help of the psychologist)
3T MRI
37- Structural, metabolic and functional data
Cardiac assessments
38- ECG
39- Ultrasound
Biological collection
40- Blood sample
41- Urinary sample
42- Superficial skin biopsy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male CTD patients having a confirmed mutation in the SLC6A8 gene,
* Aged \> 5 to \< 35 years
* Whose maternal language is French,
* Having signed the informed consent and/or for whom parents/legal guardian have signed the informed consent,
* Affiliated to national Health Insurance system or parents/legal guardian affiliated to national health insurance system.
Female CTD patients (n=15)
* Female CTD patients having a confirmed mutation in the SLC6A8 gene,
* Aged \> 5 to \< 60 years,
* Whose maternal language is French,
* Having signed the informed consent and/or for whom parents/legal guardian have signed the informed consent.
* Affiliated to national Health Insurance system (sécurité sociale) or parents/legal guardian affiliated to national health insurance system
Sex- and chronological age-matched controls (n=24)
* Male
* Aged \> 5 to \< 35 years
* Whose maternal language is French,
* Having signed the informed consent and/or for whom parents/legal guardian have signed the informed consent,
* Affiliated to national health insurance system or parents/legal guardian affiliated to national health insurance system.
Sex- and chronological age-matched female controls (n=15)
* female,
* Aged \> 5 to \< 60 years,
* Whose maternal language is French,
* Having signed the informed consent and/or for whom parents/legal guardian have signed the informed consent
* Affiliated to national Health Insurance system (sécurité sociale) or parents/legal guardian affiliated to national health insurance system
Sex- and mental age-matched controls (n=39)
* Male and female
* Aged \> 2 to \< 8 years
* Whose maternal language is French,
* For whom parents/legal guardian have signed the informed consent,
* Affiliated to national health insurance system or parents/legal guardian affiliated to national health insurance system.
Typically developed children (n=80)
* Male and female
* Aged \> 2 to \< 8 years
* Whose maternal language is French,
* For whom parents/legal guardian have signed the informed consent,
* Affiliated to national health insurance system or parents/legal guardian affiliated to national health insurance system.
Sex- and chronological age-matched controls and Sex- and mental age-matched controls, aged \< 8 years, could also be included in the Typically developed children group, as the data from the Typically developed children are only necessary to complete the developmental trajectory of the new tasks.
CTD patients (n=39):
* Having a contraindication to the MRI examination (people using a pacemaker or an insulin pump, people wearing a metal prosthesis or an intracerebral clip, and claustrophobic subjects),
* Refusal of the subject and/or the subject's parents to be informed of possible abnormalities detected by MRI,
* Refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected during the cardiac assessment.
Sex- and chronological age-matched controls (n=39)
* History of neurological or psychiatric disorder,
* Repetition of a grade,
* Learning disability requiring rehabilitation (speech therapy, psychomotor or oculomotor therapy),
* For participants agreeing on performing the MRI examination, having a contraindication to the MRI examination (use of a pacemaker or an insulin pump, people wearing a metal prosthesis or an intracerebral clip, and claustrophobic subjects) and refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected by MRI.
Sex- and mental age-matched controls (n=39)
* History of neurological or psychiatric disorder,
* Repetition of a grade,
* Learning disability requiring rehabilitation (speech therapy, psychomotor or oculomotor therapy).
Typically developed children (n=80)
* History of neurological or psychiatric disorder,
* Repetition of a grade,
* Learning disability requiring rehabilitation (speech therapy, psychomotor or oculomotor therapy).
2 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Woman, mother and child hospital, Hospices Civils de Lyon
Bron, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A02063-40
Identifier Type: OTHER
Identifier Source: secondary_id
69HCL21_0655
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.